Lifecore Biomedical Warning Letter Spotlights Intergel Adverse Event Issues
This article was originally published in The Gray Sheet
Executive Summary
Lifecore Biomedical's efforts to bring its Intergel adhesion prevention solution back to the U.S. market may be slowed by a recent warning letter citing failure to report adverse events to FDA in a timely manner